A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
10/2002
10/03/2002	US20020143008 CRF receptor antagonists and methods relating thereto
10/03/2002	US20020143004 Allosteric adenosine receptor modulators
10/03/2002	US20020143003 As serotonin, norepinephrine and dopamine reuptake inhibitors, for therapy of central nervous system and other disorders
10/03/2002	US20020143002 Estradiol-16alpha-carboxylic acid esters as locally active estrogens
10/03/2002	US20020143000 Administering 17 alpha -fluoralkylated progesterone receptor antagonist to female during the post-ovulatory phase of the endometrial cycle forinhibiting the occurrence of advanced endometrium maturation
10/03/2002	US20020142999 Topical ophthalmic, otic or nasal drug for therapy of bacterial infections
10/03/2002	US20020142996 Use of bisphosphonic acids for treating angiogenesis
10/03/2002	US20020142995 To enhance the ability of mammalian red blood cells to deliver oxygen, by delivering ligand for the allosteric site of hemoglobin to the cytoplasm of the red blood cells
10/03/2002	US20020142994 Bisphosphonate conjugates and methods of making and using the same
10/03/2002	US20020142992 Cellulosic foam compositions
10/03/2002	US20020142991 Treating or preventing drug toxicity using a toxicity reducing amount of N-acetylcysteine
10/03/2002	US20020142990 Locally administering to a human an axon of neuron therapeutically effective amount of activator of cyclic nucleotide dependent protein kinase, whereby growth of axon is promoted; detecting a resultant growth promotion of axon
10/03/2002	US20020142985 Therapeutic compositions and methods of treating glycolipid storage related disorders
10/03/2002	US20020142984 Administering a positively charged liposome to animal, wherein positively charged liposome is associated with nucleic acid molecule, wherein nucleic acid molecule is in operable association with a promoter
10/03/2002	US20020142983 MUC-1 antagonists and methods of treating immune disorders
10/03/2002	US20020142982 Method for regulating angiogenesis
10/03/2002	US20020142980 Nucleic acid molecules with novel chemical compositions capable of modulating gene expression
10/03/2002	US20020142974 Immune activation by double-stranded polynucleotides
10/03/2002	US20020142972 Antiparasitic formulation
10/03/2002	US20020142970 Administering an effective dose of angiotensin converting enzyme(ACE) inhibitor to the healthy subject, whereby the risk of cardiovascular disease in subject is prevented or significantly reduced
10/03/2002	US20020142969 Using didepsipeptide for the control of endoparasites in medicine and veterinary medicine
10/03/2002	US20020142968 For therapeutic and/or prophylactic treatment of idiopathic and adult respiratory distress syndrome, pulmonary fibrosis following treatment with radiation or chemotherapy, septic shock, septicemia, inflammatory responses
10/03/2002	US20020142967 Thrombin inhibitors
10/03/2002	US20020142956 Administering an agent which triggers anion efflux in respiratory tissue via the activation of a secretin receptor for therapy of cystic fibrosis
10/03/2002	US20020142950 Methods for enhancing the bioavailability of a drug
10/03/2002	US20020142948 Methods for administration of antibiotics
10/03/2002	US20020142947 By muta-synthesis using a mutated micro-organism to influence the biosynthesis of at least one of the precursors of group B streptogramines; mutant strain employed is preferably derived from the strain S. pristinaespiralis SP92
10/03/2002	US20020142945 Immunomodulatory methods using carbohydrate antigens
10/03/2002	US20020142944 Treatment of ocular disorders
10/03/2002	US20020142943 A drug and an agent capable of inducing the dephosphorylation of phosphorylated serine and/or threonine residue of p100 and/or p120, wherein the ability of the drug to cross a physiological barrier is improved.
10/03/2002	US20020142942 Method for treating premenstrual or late luteal phase syndrome
10/03/2002	US20020142941 Intraductal treatment targeting methylated promoters in breast cancer
10/03/2002	US20020142940 Method of inhibiting viral infection using HMG-COA reductase inhibitors and isoprenylation inhibitors
10/03/2002	US20020142448 Antibody for use in the diagnosis, treatment and prevention of bone disorders and cancer
10/03/2002	US20020142372 Fragments of cr1 and their use
10/03/2002	US20020142364 Evaluating microbiocidal activity of perfuming agent; obtain sample, solubilize tests compound, incubate with bacteria, reduce bacterial concentration, spread, monitor propagation of bacteria, compare to control
10/03/2002	US20020142359 Monoclonal antibody to CEA, conjugates comprising said antibody, and their therapeutic use in an adept system
10/03/2002	US20020142353 Connective tissue growth factor (CTGF) and methods of use
10/03/2002	US20020142330 Novel glutamate receptor modulatory proteins and nucleic acid molecules and uses therefor
10/03/2002	US20020142327 Expression analysis of smarc nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
10/03/2002	US20020142089 Oil composition
10/03/2002	US20020142054 Laxative; anticholesterol agents
10/03/2002	US20020142052 Mixture of carnitine, ferulic acid and vitamins
10/03/2002	US20020142049 Precipitating drug as solid
10/03/2002	US20020142048 Injectable pharmaceutical composition comprising coated particles of camptothecin
10/03/2002	US20020142045 Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect
10/03/2002	US20020142043 Powder containing fat-soluble drug
10/03/2002	US20020142041 Gastrointestinal mucosa-adherent matrixes, pharmaceutical preparations and a coating composition
10/03/2002	US20020142040 Antibacterial composition for topical administration containing antibiotic
10/03/2002	US20020142038 Rapid disintegration; taste
10/03/2002	US20020142035 Metering and packaging of controlled release medication
10/03/2002	US20020142034 Orally disintegrable tablets
10/03/2002	US20020142033 Administering an anticholinergic agent; side effect reduction
10/03/2002	US20020142028 Hormone replacement therapy method
10/03/2002	US20020142025 Mixture of proteins, carbohydrates, methionine, cysteine, folic acid, pyridoxal and zinc
10/03/2002	US20020142023 Insecticide, miticide
10/03/2002	US20020142018 Mixture of alcohol and water; presurgery scrub
10/03/2002	US20020142013 Cholesterol sulfate and amino sugar compositions for enhancement of stratum corneum function
10/03/2002	US20020142012 Use of flavonoids as immunomodulating or immuno-protective agents in cosmetic and dermatological preparations
10/03/2002	US20020142001 DNA immunization against Chlaymdia infection
10/03/2002	US20020142000 Genetic engineering
10/03/2002	US20020141982 Gene therapy methods using bone marrow-derived cells
10/03/2002	US20020141980 Convection-enhanced delivery of AAV vectors
10/03/2002	US20020141972 Administering protein and antiinflection agent
10/03/2002	US20020141966 Compositions for treatment of malignant effusions, and methods of making and using the same
10/03/2002	US20020141964 Hemostatic agent for a bleeding wound: an oxyacid salt which promotes clotting, and an insoluble cation exchange material that forms a protective cover over the wound
10/03/2002	US20020141959 Antimicrobial skin preparations containing organosilane quaternaries
10/03/2002	US20020141956 Skin whiteners containing hydroxytetronic acid derivatives
10/03/2002	US20020141953 Topical; carrier and one of 3,3'-thiodipropionic acid, thiazolidine-2-carboxylic acid, and kaempferol-7-glucoside, or their derivatives
10/03/2002	US20020141952 Dermatological compositions and methods
10/03/2002	US20020141947 Biocompatible particles having therapeutic, prophylactic or diagnostic agent, and of given mass mean diameter and aerodynamic diameter; at least 46% of the mass of particles are deposited after the first bifurcation of the lungs
10/03/2002	US20020141946 Formulation of dipalmitoylphosphatidyl choline (DPPC), insulin and sodium citrate
10/03/2002	US20020141945 Characteristic glass transition temperature (Tg) and a recommended storage temperature (Ts), glassy matrix and drug within the glassy matrix; unit dosage; stable dispersion over time
10/03/2002	US20020141944 Stable pharmaceutical budersonide preparation for producing propellant-free aerosols
10/03/2002	US20020141941 PSCA: prostate stem cell antigen and uses thereof
10/03/2002	US20020139938 Sensitization of cells with porphyrins, then exposing to radiation and grafting; photodynamic therapy
10/03/2002	CA2783647A1 Histone deacetylase inhibitors
10/03/2002	CA2692295A1 Combined use of methylol-transfer agents and fas-ligands in the treatment of cancer
10/03/2002	CA2445125A1 Microemulsions as precursors to solid nanoparticles
10/03/2002	CA2444841A1 Increasing phosphorus uptake from the gut of dairy cows by supplementing with 1-alpha-hydroxylated vitamin d
10/03/2002	CA2442576A1 Bioactivity of methyl palmitate obtained from a mangrove plant salvadora persica l
10/03/2002	CA2442573A1 Process for the preparation of benazepril
10/03/2002	CA2442280A1 A stable pharmaceutical composition of pravastatin
10/03/2002	CA2442178A1 2-amino-propanol derivatives
10/03/2002	CA2442089A1 Nucleic acid molecules encoding a transmembran serine protease 9, the encoded polypeptides and methods based thereon
10/03/2002	CA2442080A1 A preparation for restenosis prevention
10/03/2002	CA2442012A1 Chemical derivatives and their use as anti-telomerase agent
10/03/2002	CA2442003A1 Methods for treating neurodegenerative diseases including alzheimer's
10/03/2002	CA2441940A1 Dental formulation
10/03/2002	CA2441933A1 Novel amides, preparation and therapeutic use as modulators of ccr-receptor activity
10/03/2002	CA2441926A1 (oxo-pyrazolo[1,5a]pyrimidin-2-yl)alkyl-carboxamides
10/03/2002	CA2441893A1 Method of attenuating reactions to skin irritants
10/03/2002	CA2441890A1 Oestrogen and fatty acid monoester as a hypolipidaemic and antidiabetic agent
10/03/2002	CA2441889A1 Methods for increasing analgesic potency and attenuating adverse excitatory effects of bimodally-acting opioid agonists by inhibiting gm1-ganglioside
10/03/2002	CA2441806A1 Inosine compounds and their use for treating or preventing an inflammation or a reperfusion disease
10/03/2002	CA2441790A1 1,2,3,4-tetrahydroisoquinolines derivatives as urotensin ii receptor antagonists
10/03/2002	CA2441768A1 Method for treatment of cancer and compositions for use therein
10/03/2002	CA2441706A1 A new essential downstream component of the wingless signalling pathway
10/03/2002	CA2441599A1 Fused pyridine derivatives for use as vanilloid receptor antagonists for treating pain
10/03/2002	CA2441588A1 Use of cytokines of the tgf-.beta. superfamily for the treatment and diagnosis of skin related disorders

1 ... 5691 5692 5693 5694 5695 5696 5697 5698 5699 5700 5701 5702 5703 5704 5705 5706 5707 5708 5709 5710 5711 ... 7860